Here is the synopsis of the "cold to Hot" session at AACR.
And the sub topics
In case anyone wants to see it.
Maybe we have a chance? Not sure if we had enough data at submission deadline.
We'll see soon.
-SY12 - Harnessing the Power of the Immune System: Turning Cold Tumors Hot
April 21, 2026, 10:15 AM - 11:45 AM
Description:
"The efficacy of checkpoint blockade immunotherapy targeting PD-1/PD-L1 interactions is enriched in patients having a T cell-inflamed tumor microenvironment (TME). As such, understanding the biology of the process of tumor cell-immune system interactions is paramount, and fundamental principles are guiding the development of novel strategies to modulate the TME to catalyze the transition of “cold” tumors into “hot”. Non-T cell-inflamed tumors lack essential immune components for anti-tumor immunity, including key subsets of dendritic cells, innate immune activation including type I IFN responses, and chemokines for T cell recruitment. Thus, multiple approaches are being pursued to bring these factors into the cold tumor TME. However, it also has become clear that non-T cell-inflamed tumors are enriched for various subsets of suppressive macrophages that impede anti-tumor immunity in a dominant-negative fashion, and novel targets and strategies are being uncovered to shift myeloid cell phenotypes to be immune-supportive. This session will discuss biologic features of tumor/host interactions, including recent data on macrophage modulation".
10:20 AM - 10:40 AM - Novel regulators of suppressive myeloid cells in the tumor microenvironment.
Thomas Frank Gajewski. University of Chicago, Chicago, IL
10:45 AM - 11:05 AM - Translating the cancer-immune dialogue
Daniel S. Peeper. Netherlands Cancer Institute, Amsterdam, Netherlands
11:10 AM - 11:30 AM - Context dependence of myeloid-mediated immunosuppression
Lawrence Fong. Fred Hutchinson Cancer Center, Seattle, WA
And the sub topics
In case anyone wants to see it.
Maybe we have a chance? Not sure if we had enough data at submission deadline.
We'll see soon.
-SY12 - Harnessing the Power of the Immune System: Turning Cold Tumors Hot
April 21, 2026, 10:15 AM - 11:45 AM
Description:
"The efficacy of checkpoint blockade immunotherapy targeting PD-1/PD-L1 interactions is enriched in patients having a T cell-inflamed tumor microenvironment (TME). As such, understanding the biology of the process of tumor cell-immune system interactions is paramount, and fundamental principles are guiding the development of novel strategies to modulate the TME to catalyze the transition of “cold” tumors into “hot”. Non-T cell-inflamed tumors lack essential immune components for anti-tumor immunity, including key subsets of dendritic cells, innate immune activation including type I IFN responses, and chemokines for T cell recruitment. Thus, multiple approaches are being pursued to bring these factors into the cold tumor TME. However, it also has become clear that non-T cell-inflamed tumors are enriched for various subsets of suppressive macrophages that impede anti-tumor immunity in a dominant-negative fashion, and novel targets and strategies are being uncovered to shift myeloid cell phenotypes to be immune-supportive. This session will discuss biologic features of tumor/host interactions, including recent data on macrophage modulation".
10:20 AM - 10:40 AM - Novel regulators of suppressive myeloid cells in the tumor microenvironment.
Thomas Frank Gajewski. University of Chicago, Chicago, IL
10:45 AM - 11:05 AM - Translating the cancer-immune dialogue
Daniel S. Peeper. Netherlands Cancer Institute, Amsterdam, Netherlands
11:10 AM - 11:30 AM - Context dependence of myeloid-mediated immunosuppression
Lawrence Fong. Fred Hutchinson Cancer Center, Seattle, WA
8
